Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Joseph Stringer
NDM
Joseph Stringer
Needham
Wall Street Analyst
★★★★☆
#475
on 13Foresight · ranked by our own returns
53%
Success Rate
+13.8%
Average Return
18 of 34 calls profitable · +9.3% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 53% of Joseph Stringer's ratings turned a profit when each position was held for 1 year — averaging +13.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

102 Buy 24 Hold 0 Sell
Joseph's Stock Coverage 20 ratings · 2026-07-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
STOK
Stoke Therapeutics
 Jul 09, 2026 BUY Strong Buy
+23.7% avg upside
18 analysts
$40.00
27.50% Upside
 -4.4%
BIOA
BioAge Labs, Inc.
 Jul 09, 2026 BUY Strong Buy
+103.4% avg upside
9 analysts
$50.00
105.46% Upside
 ·
ANNX
Annexon Biosciences
 Jul 09, 2026 BUY Strong Buy
+137.6% avg upside
13 analysts
$11.00
89.68% Upside
 ·
IONS
Ionis Pharmaceuticals
 Jul 09, 2026 BUY Strong Buy
+37.8% avg upside
43 analysts
$86.00
47.71% Upside
 -9.4%
VRTX
Vertex Pharmaceuticals
 Jul 07, 2026 HOLD Strong Buy
-9.5% avg upside
61 analysts
 — -7.1%
PCVX
Vaxcyte
 Jun 26, 2026 BUY Strong Buy
+73.3% avg upside
15 analysts
$110.00
88.87% Upside
 +3.9%
ALNY
Alnylam Pharma
 Jun 24, 2026 BUY Strong Buy
+16.0% avg upside
51 analysts
$510.00
70.78% Upside
 +23.5%
RYTM
Rhythm Pharmaceuticals
 Jun 15, 2026 BUY Strong Buy
+12.0% avg upside
19 analysts
$130.00
19.83% Upside
 +27.6%
GILD
Gilead Sciences
 Jun 12, 2026 BUY Strong Buy
-8.3% avg upside
66 analysts
$170.00
30.86% Upside
 +4.1%
STTK
Shattuck Labs
 Jun 08, 2026 BUY Strong Buy
+249.8% avg upside
14 analysts
$17.00
156.01% Upside
 +83.6%
PHAT
Phathom Pharmaceuticals
 Jun 01, 2026 BUY Strong Buy
+127.6% avg upside
14 analysts
$28.00
122.05% Upside
 +36.5%
PLRX
Pliant Therapeutics
 May 12, 2026 HOLD Buy
+1889.7% avg upside
21 analysts
 — -4.2%
VIR
Vir Biotechnology
 May 07, 2026 BUY Strong Buy
+162.5% avg upside
16 analysts
$18.00
80.77% Upside
 +7.4%
MRNA
Moderna
 May 01, 2026 HOLD Hold
+1.6% avg upside
38 analysts
$45.94
32.75% Downside
 +68.8%
LXRX
Lexicon Pharmaceuticals
 Apr 21, 2025 HOLD Buy
+79.8% avg upside
9 analysts
 — +221.1%
TVRD
Tvardi Therapeutics
 Aug 16, 2024 HOLD Strong Buy
+452.6% avg upside
23 analysts
 — +99.0%
TBPH
Theravance Biopharma
 Dec 23, 2022 HOLD Buy
+8.9% avg upside
18 analysts
 — -2.3%
ACAD
ACADIA Pharmaceuticals
 Aug 05, 2021 BUY Strong Buy
+37.4% avg upside
42 analysts
$26.00
0.90% Downside
 -14.6%
NBIX
Neurocrine
 Aug 04, 2021 HOLD Strong Buy
-1.8% avg upside
37 analysts
 — +2.9%
CRSP
Crispr Therapeutics AG
 Apr 28, 2021 BUY Buy
+41.0% avg upside
41 analysts
$170.00
218.59% Upside
 -61.9%
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Joseph Stringer — Frequently Asked Questions
How accurate are Joseph Stringer's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Joseph's ratings were profitable over a one-year hold, with an average return of +15.5% per rating, or +10.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Joseph ranked on 13Foresight?
Joseph Stringer is currently ranked #475 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Joseph cover?
Joseph most recently has ratings on STOK, BIOA, ANNX, IONS, VRTX, PCVX, ALNY, RYTM, GILD, STTK, PHAT, PLRX and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.